---
figid: PMC6505627__oncotarget-10-2738-g002
figtitle: 'BCR: a promiscuous fusion partner in hematopoietic disorders'
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC6505627
filename: oncotarget-10-2738-g002.jpg
figlink: /pmc/articles/PMC6505627/figure/F2/
number: F2
caption: BCR-ABL, BCR-FGFR1, and BCR-RET all activate STAT, MAPK, and AKT, while BCR-JAK2
  only activates the STAT pathway, and signaling by BCR-PDGFRA remains to be elucidated.
  All drugs shown inhibit the kinase activity of each fusion protein and has been
  used in patients who are positive for the respective oncogenic fusion.
papertitle: 'BCR: a promiscuous fusion partner in hematopoietic disorders.'
reftext: Malalage N. Peiris, et al. Oncotarget. 2019 Apr 12;10(28):2738-2754.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9301625
figid_alias: PMC6505627__F2
figtype: Figure
redirect_from: /figures/PMC6505627__F2
ndex: 2d367950-df00-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6505627__oncotarget-10-2738-g002.html
  '@type': Dataset
  description: BCR-ABL, BCR-FGFR1, and BCR-RET all activate STAT, MAPK, and AKT, while
    BCR-JAK2 only activates the STAT pathway, and signaling by BCR-PDGFRA remains
    to be elucidated. All drugs shown inhibit the kinase activity of each fusion protein
    and has been used in patients who are positive for the respective oncogenic fusion.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BCR
  - RN7SL263P
  - FGFR1
  - ABL1
  - MTTP
  - DSP-AS1
  - ABL2
  - RET
  - JAK2
  - PDGFRA
  - JAK1
  - JAK3
  - TYK2
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - AKT1
  - AKT2
  - AKT3
  - Imatinib
  - Ruxolitinib
  - Ponatinib
  - Dasatinib
  - Sorafenib
  - Nilotinib
  - Bosutinib
  - Dovitinib
  - Cancer
---
